Delayed hypersensitivity and cytokine release syndrome to paclitaxel and nab-paclitaxel: a case report

Abstract

Hypersensitivity reactions (HSRs) to paclitaxel, particularly those mediated by the solubilizer Cremophor^® EL, are common, occurring in approximately 10% of patients despite premedication. Nab-paclitaxel, a newer formulation using human serum albumin as the vehicle, is generally considered a safer alternative due to a lower rate of HSRs. We present the case of a 44-year-old woman with breast cancer who developed severe HSRs following multiple doses of paclitaxel and carboplatin. Despite standard premedication, she experienced fever, erythematous skin eruptions, arthralgias, and systemic symptoms following her fourth and fifth cycles of treatment. Subsequent administration of nab-paclitaxel also elicited a similar severe reaction. Skin testing revealed a positive reaction to paclitaxel, but not to carboplatin, suggesting sensitization to paclitaxel. In the context of the similar reaction to nab-paclitaxel, this suggests sensitization to the taxane moiety itself rather than to the solubilizer. The combination of features consistent with both type IV hypersensitivity and cytokine release syndrome further complicates the presentation as well. To our knowledge, this is the first reported case of cross-reactivity between paclitaxel and nab-paclitaxel, challenging the assumption that nab-paclitaxel is always a safe alternative. This emphasizes the need for vigilance and thorough evaluation in patients experiencing atypical chemotherapy reactions, as cytokine release reactions may play a role even in the absence of immunotherapy. It also raises the concern that alternative formulations like nab-paclitaxel may not always be safe in patients with atypical or severe reactions, as they could possibly be sensitized to the taxane moiety itself.

Keywords

Drug allergy / type IV hypersensitivity / cytokine release reaction / paclitaxel / skin testing / case report

References

[1] Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvão VR, Berlin ST, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016; 137: 1154-64.e12.

[2] Picard M, Castells MC. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review. Clin Rev Allergy Immunol. 2015; 49: 177-91.

[3] Pagani M, Bavbek S, Dursun AB, Bonadonna P, Caralli M, Cernadas J, et al. Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study. J Allergy Clin Immunol Pract. 2019; 7: 990- 7.

[4] Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. ; ENDA/EAACI Drug Allergy Interest Group. Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013; 68: 702-12.

[5] Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International Consensus on drug allergy. Allergy. 2014; 69: 420-37.

[6] Lee EY, Jakubovic BD. Interleukin-6 and cytokine release syndrome: A new understanding in drug hypersensitivity reactions. Ann Allergy Asthma Immunol. 2023; 130: 178-84.

[7] Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. J Allergy Clin Immunol. 2018; 142: 159-70.e2.

[8] Bukacel DG, Bander R, Ibrahim RB. Cross-reactivity between paclitaxel and hazelnut: a case report. J Oncol Pharm Pract. 2007; 13: 53-5.

[9] Hazrati R, Zare N, Asghari-Zakaria R, Sheikhzadeh P, Johari-Ahar M. Factors affecting the growth, antioxidant potential, and secondary metabolites production in hazel callus cultures. AMB Express. 2022; 12: 109.

[10] Tavera MAU, Angel D, Madrigal-Burgaleta R, Berges P, Alvarez-Cuesta E, Perez Arango R. Delayed Reaction to Paclitaxel. J Allergy Clin Immunol. 2013; 131: AB164.

[11] Cesarin M, Lane M, Droney L, Reedy C. P10: Successful demonstration of delayed hypersensitivity reaction to paclitaxel with delayed read intradermal drug testing. Intern Med J. 2023; 53: 8.

[12] Villarreal-González RV, González-Díaz S, Vidal-Gutiérrez O, de la Cruz-de la Cruz C, Pérez-Ibave DC, Garza-Rodríguez ML. Interleukin-6 as a biomarker of hypersensitivity reactions in chemotherapeutics and monoclonal antibodies. J Oncol Pharm Pract. 2024; 30: 1294-301.